GH Share Price Performance
US$44.59
10.63 (31.30%)
25.3% undervalued intrinsic discount
US$59.67
Fair Value
Price US$44.59
AnalystConsensusTarget US$59.67
Fair ValueUS$59.67
Share PriceUS$44.59
25.3% undervalued intrinsic discount
GH Community Narratives
AN
Fair Value US$59.67 25.3% undervalued intrinsic discount
Medicare Coverage Of Reveal And Shield's FDA Approval Will Expand Market Reach
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
Recent GH News & Updates
No updates
Guardant Health, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -3.32
- Gross Margin
- 62.84%
- Net Profit Margin
- -49.93%
- Debt/Equity Ratio
- -365.2%
Guardant Health, Inc. Competitors
About GH
- Founded
- 2011
- Employees
- 2010
- CEO
- WebsiteView website
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform. In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
U.S. Market Performance
- 7 Days: -0.2%
- 3 Months: 12.2%
- 1 Year: 22.4%
- Year to Date: 7.7%
In the last week, the market has stayed flat, however the Communication Services sector stood out, gaining 3.4%. As for the longer term, the market has risen 22% in the past 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading